<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="657256" id="root" date="1997-06-12" xml:lang="en">
<title>USA: Vertex, Lilly in hepatitis C alliance.</title>
<headline>Vertex, Lilly in hepatitis C alliance.</headline>
<dateline>CAMBRIDGE, Mass. 1997-06-12</dateline>
<text>
<p>Vertex Pharmaceuticals Inc and Eli Lilly and Co said Thursday they agreed to collaborate on research to treat hepatitis C infections, with Lilly to make research support and milestone payments to Vertex that could total more than $40 million.</p>
<p>Vertex has also agreed to sell Lilly $10 million worth of its stock.</p>
<p>The two companies said they will research, develop and commercialize protease inhibitors for the treatment of chronic infection caused by the hepatitis C virus.  </p>
<p>&quot;This collaboration combines Vertex's drug discovery capabilities with Lilly's clinical development and marketing expertise,&quot; Joshua Boger, Vertex president, said in a statement.  &quot;We are confident that Lilly's participation in this program will accelerate our effort to develop and introduce a new treatment for the millions of people infected with hepatitis C worldwide.&quot;</p>
<p>Under the terms of the agreement, Vertex and Lilly will jointly manage the research, development, manufacturing and marketing of drug emerging from the collaboration.  </p>
<p>Vertex will have primary responsibility for drug design, process development and pre-commercial drug substance manufacturing.  Lilly will have primary responsibility for formulation, preclinical and clinical development, and global marketing, the companies said.</p>
<p>In addition, Vertex has the option to supply 100 percent of Lilly's commercial drug substance supply needs.</p>
<p>Vertex will receive royalties on product sales. If Vertex exercised the commercial supply option, it will receive drug supply payments rather than royalties outside of the United States and Japan, they added.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C11">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
  <code code="GHEA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-12"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-06-12"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-06-12"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="CAMBRIDGE, Mass."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
